(randomness with knowable probabilities) is more realistically 'uncertainty' (randomness with unknowable probabilities). 1 In reality, in many situations it is not a matter of knowing what we don't know, but of not knowing how much we don't know. 2 Given the uncertainties involved in hazard identification and exposure evaluation, and therefore in risk assessment, public health policies must be introduced with caution and kept under continuous and rigorous review, with systems in place to ensure that policies are revised in line with new knowledge, without undue delay.
The Risk of Tobacco Smoking
A few years ago, we became concerned about developments in relation to the US Food and Drug Administration (FDA) requirements for existing and so-called 'new' tobacco products, since claims about the greater safety of the new products would have to be based on acceptable risk assessments. 3 We feared that this might result in a dramatic increase in animal testing via inhalation toxicity procedures, which, though highly expensive and likely to cause great animal suffering, would yield data of very limited relevance when applied to humans. We argued that the intelligent and integrated use of in vitro, mechanism-based, target tissue-oriented technologies, relevant to respiratory disease and respiratory toxicity, could provide a much more satisfactory basis for hazard prediction, and therefore for risk assessment.
The Safety of Electronic Cigarettes
We became especially concerned about one particular type of new smoking product, electronic 4 Of particular concern was the statement that "while, vaping may not be 100% safe, most of the chemicals causing smoking-related disease are absent and the chemicals present pose limited danger" … so "the current best estimate is that e-cigarette use is around 95% less harmful to health than smoking". We reviewed the situation, and argued that recommendations made by bodies such as PHE should not be based merely on apparent plausibility and expert opinions, but rather on high-quality scientific evidence. This would avoid bias and conjecture, and would permit a proper risk assessment. We further pointed out that such evidence could only be provided by integrated in silico, in vitro and clinical studies, for both scientific and logistical reasons. 5 Astonishingly, since it was published in 2015, our article has had more than 5,200 reads on ResearchGate, a professional network for scientists, with more than 15 million members from all over the world.
There is now a vast literature on ECs, in which a wide range of questions and concerns about their development, promotion and use are frequently raised.
Report of the House of Commons Science and Technology Committee
Known to one of us as his former Member of Parliament, the Rt Hon. Norman Lamb MP, Chairman of the House of Commons Science and Technology Committee, came to see us in Norwich, and we explained our concerns about the EC situation.
Not necessarily because of Mr Lamb's meeting with us, and against the background of disagreement and uncertainty over the health risks of ECs, the Committee decided to examine the evidence on their health impacts and on their role as a smoking cessation tool. The Committee received 100 pieces of written evidence, and held five oral evidence sessions between January and May 2018, hearing from 25 witnesses. Our review was one of the pieces of written evidence, but we were not invited to attend any of the oral sessions.
The Committee published its 66-page report on 17 August 2018. 6 We have sympathy for the Committee, given the wide variety and complexity of the scientific and technical issues to be dealt with. Nevertheless, with regret, we have to say that we were extremely disappointed by virtually all its conclusions and recommendations, for reasons which we will refer to briefly here, although we will be publishing a more-detailed analysis in due course.
In the Summary of the report, it is stated that ECs "are substantially less harmful -by around 95% -than conventional cigarettes". The uncertainties about any long-term effects of using ECs were recognised, but it was concluded that the risk was worth taking, since the risk of not doing so would result in the continuing use of conventional cigarettes "which are substantially more harmful". There are, of course, other ways of replacing the use of conventional cigarettes, which do not involve deliberately taking complex mixtures of chemicals into the respiratory system.
That ECs are less harmful than conventional cigarettes is plausible, even likely, but the unfounded 95% less harmful statement will undoubtedly encourage EC users to believe that ECs are 'safe', whereas, in reality, the evidence that could support such a belief, or support an acceptable risk assessment, is totally lacking.
Part of the problem is that most, if not all, of the 25 individuals invited to give oral evidence were either from the tobacco industry or closely-related companies, or from organisations known to recommend the use of ECs. The Committee did not meet any completely independent toxicologists or individuals with strong views that the use of ECs is unacceptably risky.
Nicotine is highly addictive, and exerts complex biochemical effects on its target cells, several of which are known to be associated with tumour development. This should have been given moreserious consideration, through consultation with independent experts, even if it was downplayed by those other experts who did meet the Committee.
There is insufficient quantitative evidence about the toxicities of the chemicals, either individually or in combination, that are contained in EC emissions, which undermines the 95% less harmful claim (i.e. risk assessment is not possible in the absence of data on hazard). It is also impossible to describe, in a satisfactory way, what exposure to EC emissions actually means, for a variety of reasons.
The contents of the various EC brands differ greatly, as does EC use (i.e. vaping behaviour) itself, which also involves a wide variety of different forms, related, for example, to: whether or not the vapour is inhaled; the number of puffs per day; intervals between puffs; EC use along with conventional cigarette use; and whether or not the user has a history of conventional smoking (and, if so, how much and for how long). There are also issues related to whether -and, if so, how often -EC users (of whatever age) progress to conventional smoking. Indeed, there are also reports that EC manufacturers are using child-friendly images to market flavoured liquids for vapourising in ECs, which contain nicotine. 7 The Committee concluded that exposure to "second-hand" EC vapour involves a "negligible health risk", so there is no rationale for treating the use of ECs and conventional smoking in the same way, e.g. in transport and other public places. But where is the evidence that this is true? If the effects of EC vapour on EC users are not known and cannot be described, then how can the effects, or lack of effects, on those around them be known?
The Inescapable Need for Evidence Scientific knowledge and understanding, and hypotheses and theories -and the policies which depend on them -should be based on evidence based on the mining and interpretation of existing data and on new experimental data.
Nowadays, recognition is also given to EvidenceBased Medicine (EBM), which integrates clinical experience and technical information in making the best possible decisions about the care of individual patients. Then there is Evidence-Based Toxicology (EBT), in which the best available evidence on the adverse effects of chemical, physical or biological agents on living organisms is integrated and used, in order to avoid, prevent or treat adverse effects in particular circumstances.
In the case of ECs, however, none of these approaches are being used effectively or consistently. Risks are being assessed in the absence of sufficient acceptable data on either hazard or exposure, and expert opinion is being accepted as a substitute for the need for scientific evidence.
This appears to be supported by an industry which seeks to replace the marketing of one unsafe and harmful product (tobacco) with an equally, or even more, profitable product (nicotine delivered via ECs). 8 
The Way Forward
The Committee did consider various ways forward, including the regulation and licensing of ECs. This would have to involve the formal and detailed descriptions of the components of the ECs supplied and of the vapour they produce.
There should also be independent research on the toxicity of these components, alone and in combination, based on the integrated use of humanrelevant, non-animal test procedures, taking into account human genetic variation. The methods are available, 9 subject to further development to answer specific questions. In parallel with this, there should be long-term clinical studies on cohorts of EC users. These studies should be relevant to the kinds of factors we have mentioned, such as inhalation or not, frequency of use, and history of conventional smoking. This should also include studies on the degrees to which conventional smokers actually succeed in giving up conventional smoking via the use of ECs.
Similarly, there should be independent studies on the benefits and risks involved in other ways of giving up tobacco smoking, with care taken to avoid bias linked to commercial interests and pressures.
Concluding Remarks
The answer to the question in the title of this Editorial is an emphatic 'No!'
We have long campaigned against the reliance of toxicity testing on the use of animal models, which provide data of questionable relevance. This is because the animals used in the models are fundamentally different from human beings in many ways -structurally and physiologically, and in terms of their susceptibility to the adverse effects of chemicals and products, and their responses to exposure to them. We have been involved in the development of modern approaches, based on in silico, in vitro and in chemico studies, of greater human relevance, designed to take account of human variation and human-specific exposures and complementing factors. What we have not done is campaign for the introduction for human use of chemicals and products which have not been subjected to rigorous testing in terms of hazard and exposure as a basis for meaningful risk assessments.
Why, then, are the authorities responsible for protecting public health -including PHE and the House of Commons Science and Technology Committee, along with the other agencies they consulted or are otherwise involved with -willing to allow the use of ECs to be promoted and encouraged, and even to suggest that they should be made available via the NHS? Yes, conventional tobacco smoking is an enormous public health problem, but there must be ways of dealing with it, other than opening up the risk of another serious public health problem.
